Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
Domenico De Berardis, Michele Fornaro, Annalisa Anastasia, et al.
Brazilian Journal of Psychiatry (2020) Vol. 42, Iss. 3, pp. 317-321
Open Access | Times Cited: 18

Showing 18 citing articles:

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis
Rebecca Strawbridge, Ben Carter, Lindsey Marwood, et al.
The British Journal of Psychiatry (2018) Vol. 214, Iss. 1, pp. 42-51
Open Access | Times Cited: 107
Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
Xiaolin Ye, Dong Wang, Huaqian Zhu, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 52
Heat-sterilized Bifidobacterium breve prevents depression-like behavior and interleukin-1β expression in mice exposed to chronic social defeat stress
Aika Kosuge, Kazuo Kunisawa, Satoshi Arai, et al.
Brain Behavior and Immunity (2021) Vol. 96, pp. 200-211
Closed Access | Times Cited: 49
Omega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study
Seema Mehdi, M Kishor, Atiqulla Shariff, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 224-224
Open Access | Times Cited: 17
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis
Isabella Berardelli, Elena Rogante, Federico Formica, et al.
Journal of Psychopharmacology (2025)
Closed Access
The effect of fish oil versus krill oil intervention on clinical symptoms and cardiometabolic risk factors in patients with major depressive disorder: A randomized placebo-controlled double-blind trial
Murat Açık, Funda Pınar Çakiroğlu, Atilla Tekın, et al.
Journal of Affective Disorders (2025)
Closed Access
Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance
Janne Kaergaard Mortensen, Grethe Andersen
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 9, pp. 1157-1166
Closed Access | Times Cited: 29
Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
Zejun Li, Shouhuan Liu, Qiuxia Wu, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 6, pp. 373-384
Open Access | Times Cited: 12
Role of Ketamine in the Treatment of Psychiatric Disorders
Sahar Derakhshanian, Maxine Zhou, Alexander Rath, et al.
Health psychology research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
Seok Woo Moon, Jee Wook Kim, Do Hoon Kim, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 4
The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature
Francesco Weiss, Bruno Pacciardi, Giulia D’Alessandro, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 531-531
Open Access | Times Cited: 1
C-reactive protein could predict the efficacy of SSRIs in clinical practice: A cohort study of large samples in the real world
Yuqian Pan, Rui Luo, Shuqi Zhang, et al.
Journal of Affective Disorders (2022) Vol. 313, pp. 251-259
Closed Access | Times Cited: 6
The costs of treatment resistant depression: evidence from a survey among Italian patients
Matteo Ruggeri, Carlo Drago, Donatella Mandolini, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2021) Vol. 22, Iss. 3, pp. 437-444
Closed Access | Times Cited: 7
A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
Rohini Bose, Syed Usman Hamdani, Faiza Aslam, et al.
Current Medical Research and Opinion (2022) Vol. 38, Iss. 5, pp. 661-671
Closed Access | Times Cited: 5
A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
Ignacio Basurte-Villamor, Pablo Vega, Carlos Roncero, et al.
Neuropsychiatric Disease and Treatment (2022) Vol. Volume 18, pp. 965-976
Open Access | Times Cited: 4
The Mechanisms Underlying the Pharmacological Effects of GuiPi Decoction on Major Depressive Disorder based on Network Pharmacology and Molecular Docking
Li‐Yuan Chen, Tianyuan Ye, Xiaolong Wang, et al.
Combinatorial Chemistry & High Throughput Screening (2022) Vol. 26, Iss. 9, pp. 1701-1728
Closed Access | Times Cited: 1
An Oppositional Tolerance Account for Potential Cognitive Deficits Caused by the Discontinuation of Antidepressant Drugs
Christian Beste, Ann‐Kathrin Stock, Lorenza S. Colzato, et al.
Pharmacopsychiatry (2021) Vol. 54, Iss. 06, pp. 252-260
Open Access | Times Cited: 1

Lorenza S. Colzato, Wenxin Zhang, Henrik Walter, et al.
Pharmacopsychiatry (2021) Vol. 54, Iss. 06
Open Access
Page 1

Scroll to top